Abstract
Several rifamycin derivatives have been developed during the last 15 years for the treatment of mycobacterial infections. For tuberculosis, rifabutin (RFB) showed strong activity and seemed to be suitable when tuberculosis patients were also treated for their AIDS infection. Rifapentine (RPT) was evaluated in patients with or without AIDS for its intermittent use. It displayed promising activity but must be strengthened in situations, such as AIDS or patients without AIDS but with cavities. Rifalazil (RLZ) has been evaluated in mice but the dosages used were much higher than those tolerated by patients. Regarding Mycobacterium avium infections, RFB showed significant prophylactic activity in humans, RPT displayed some activity in mice and RLZ showed modest activity in mice.
Keywords: tuberculosis, mycobacterium avium infections, rifabutin, rifapentine, rifalazil
Current Pharmaceutical Design
Title: In Vitro and In Vivo Activities of New Rifamycin Derivatives Against Mycobacterial Infections
Volume: 10 Issue: 26
Author(s): N. Lounis and G. Roscigno
Affiliation:
Keywords: tuberculosis, mycobacterium avium infections, rifabutin, rifapentine, rifalazil
Abstract: Several rifamycin derivatives have been developed during the last 15 years for the treatment of mycobacterial infections. For tuberculosis, rifabutin (RFB) showed strong activity and seemed to be suitable when tuberculosis patients were also treated for their AIDS infection. Rifapentine (RPT) was evaluated in patients with or without AIDS for its intermittent use. It displayed promising activity but must be strengthened in situations, such as AIDS or patients without AIDS but with cavities. Rifalazil (RLZ) has been evaluated in mice but the dosages used were much higher than those tolerated by patients. Regarding Mycobacterium avium infections, RFB showed significant prophylactic activity in humans, RPT displayed some activity in mice and RLZ showed modest activity in mice.
Export Options
About this article
Cite this article as:
Lounis N. and Roscigno G., In Vitro and In Vivo Activities of New Rifamycin Derivatives Against Mycobacterial Infections, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383287
DOI https://dx.doi.org/10.2174/1381612043383287 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Hot Topic: Emerging Therapeutic Targets in Inflammation and Allergy Drug Discovery from Patent Perspective)
Recent Patents on Inflammation & Allergy Drug Discovery Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism Editorial [Revisiting the Paris Declaration: Pharmacogenomics and Personalized Medicine as Accelerators for Development Aid and Effectiveness]
Current Pharmacogenomics and Personalized Medicine In Search of Drug Targets for Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Aging in Bacteria, Immortality or Not-A Critical Review
Current Aging Science Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus
Current Enzyme Inhibition <i>In silico</i> Modeling of Antimalarial Protein Kinase Inhibitors
Letters in Drug Design & Discovery Interaction Between Two Residues in the Inter-Domain Interface of Escherichia coli Peptidase N Modulates Catalytic Activity
Protein & Peptide Letters Genomics and the Prospects for the Discovery of New Targets for Antibacterial and Antifungal Agents
Current Pharmaceutical Design The Mechanism by which the Phenothiazine Thioridazine Contributes to Cure Problematic Drug-Resistant Forms of Pulmonary Tuberculosis: Recent Patents for “New Use”
Recent Patents on Anti-Infective Drug Discovery 1, 2, 4-triazoles Clubbed Pyrimidine Compounds with Synthesis, Antimicrobial, Antituberculosis, Antimalarial, and Anti-protozoal Studies
Letters in Organic Chemistry 2-Aminoimidazole, Glycociamidine and 2-Thiohydantoin-Marine Alkaloids as Molecular Inspirations for the Development of Lead Structures
Current Drug Targets Diagnosis and Therapeutic Approaches to Transthyretin Amyloidosis
Current Medicinal Chemistry Significant Induction of Soluble TNFR2 Compared with TNFR1 in Serum Samples of HIV Patients with or without Antiretroviral Medication
Infectious Disorders - Drug Targets Synthesis, admetSAR Predictions, DPPH Radical Scavenging Activity, and Potent Anti-mycobacterial Studies of Hydrazones of Substituted 4-(anilino methyl) benzohydrazides (Part 2)
Current Computer-Aided Drug Design A Universal, Fully Automated High Throughput Screening Assay for Pyrophosphate and Phosphate Release from Enzymatic Reactions
Combinatorial Chemistry & High Throughput Screening Insights in Nanoparticle-Bacterium Interactions: New Frontiers to Bypass Bacterial Resistance to Antibiotics
Current Pharmaceutical Design Optimization of Supercritical Fluid Extraction for <i>Mariposa Christia Vespertilionis</i> Leaves Towards Yield by Using Response Surface Methodology
Recent Innovations in Chemical Engineering Dendritoma Vaccine for Cancer: A Hopeful Approach
Current Cancer Therapy Reviews Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells
Current Immunology Reviews (Discontinued)